Key result
Higher uromodulin linked to ~43% lower AVR risk per SD in aortic regurgitation.
Why the study?
Prior studies on renal dysfunction in aortic regurgitation predominantly focused on advanced stages and post-interventional outcomes, leaving limited insight into pre-interventional disease progression or biologically informed risk stratification.
Does higher circulating uromodulin level predict a lower risk of aortic valve replacement in patients with aortic regurgitation?
Cohort (n=2,493)
Yes
Does higher circulating uromodulin level predict a lower risk of aortic valve replacement in patients with aortic regurgitation?
Hazard Ratio: 0.57 (95% CI 0.34–0.98)
p-value: p=0.041
May support uromodulin for risk stratification in aortic regurgitation; leaves open causal role and need for prospective validation.
Background Aortic regurgitation (AR) frequently remains asymptomatic for prolonged periods, with guideline recommendations for intervention largely guided by imaging-based assessment of left ventricular remodeling. While renal dysfunction has been linked to adverse outcomes in AR, prior studies have predominantly focused on advanced disease stages and post-interventional outcomes, with limited data on pre-interventional progression, offering limited insight into pre-interventional disease progression or biologically informed approaches to risk stratification. Methods We investigated renal biomarkers in individuals with AR from the UK Biobank ( n = 2,493) and assessed associations with time to aortic valve replacement (AVR) using Cox proportional hazards models. Associations with cardiovascular imaging and hemodynamic phenotypes were examined via logistic regression. To place clinical findings in a biological context, we performed genome-wide colocalization analyses between AR phenotypes, blood pressure, and renal traits, followed by regulatory annotation, single-cell RNA sequencing (Kidney Cell Atlas), and phenome-wide association analyses. Results Among patients with AR, higher circulating UMOD levels were independently associated with a lower risk of subsequent AVR (adjusted HR per SD 0.57, 95% CI 0.34–0.98; p = 0.041), whereas conventional renal markers (creatinine, urea, microalbumin) showed no association. UMOD levels were strongly associated with lower arterial stiffness ( β = −5.32 ± 0.27; p < 0.001 and lower systolic blood pressure ( β = −0.91 ± 0.13; p < 0.001), both associated with disease progression, but not with left ventricular volumes. Genome-wide colocalization identified a shared genetic signal at the UMOD locus linking AR, blood pressure, and kidney function. Regulatory annotation and single-cell data localized UMOD expression to the thick ascending limb of Henle's loop, supporting a tubular-specific mechanism. Phenome-wide analyses further implicated UMOD variants in renal tubular and hemodynamic traits. Conclusions These findings identify uromodulin as a genetically anchored, kidney-specific biomarker associated with pre-interventional progression and timing of valve intervention in AR. Our study shifts the renal–AR paradigm from post-operative risk modification toward a mechanistically grounded model of tubular-driven disease progression, with implications for earlier risk stratification and surgical referral.
No takes yet. Share an insight, caveat, or question.
Ghanbari et al. (2026) conducted a cohort in Aortic regurgitation (n=2,493). Circulating uromodulin (UMOD) levels vs. Lower UMOD levels was evaluated on Time to aortic valve replacement (AVR) (HR 0.57, 95% CI 0.34-0.98, p=0.041). Higher circulating uromodulin levels were independently associated with a lower risk of subsequent aortic valve replacement in patients with aortic regurgitation (adjusted HR per SD 0.57).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: